Bill Sponsor
House Bill 2283
116th Congress(2019-2020)
CHANGE Act of 2019
Introduced
Introduced
Introduced in House on Apr 10, 2019
Overview
Text
Introduced
Apr 10, 2019
Latest Action
Apr 11, 2019
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
2283
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
California
Democrat
District of Columbia
Republican
Florida
Republican
Florida
Democrat
Georgia
Republican
Illinois
Democrat
Maryland
Democrat
Massachusetts
Democrat
Massachusetts
Republican
Michigan
Republican
Missouri
Democrat
Nevada
Democrat
New Hampshire
Democrat
New Jersey
Republican
New Jersey
Democrat
New Jersey
Democrat
New York
Republican
Oklahoma
Republican
Pennsylvania
Democrat
Pennsylvania
Democrat
Pennsylvania
Democrat
Washington
Democrat
Wisconsin
House Votes (0)
Senate Votes (0)
No House votes have been held for this bill.
Summary

Concentrating on High-value Alzheimer's Needs to Get to an End Act of 2019 or the CHANGE Act of 2019

This bill modifies the requirements under Medicare for diagnosing and treating Alzheimer's disease and other cognitive impairments in older adults. Specifically, the bill expands the cognitive impairment detection benefit during annual wellness visits to require the use of validated detection tools and documentation of the results in the patient's medical record. Further, when a cognitive impairment is detected, the patient must be referred to an appropriate diagnostic service provider and other specified supports.

Additionally, the Centers for Medicare and Medicaid Services must implement Medicare policies that increase the identification and response to patients' Alzheimer's disease risk factors and incentivize providers to utilize high-quality cognitive impairment diagnosis practices.

The Government Accountability Office also must conduct a study of policies that may accelerate progress in Alzheimer's disease research and enhance the quality of care for individuals diagnosed with Alzheimer's disease.

Text (1)
April 10, 2019
Actions (3)
04/11/2019
Referred to the Subcommittee on Health.
04/10/2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
04/10/2019
Introduced in House
Public Record
Record Updated
Nov 1, 2022 7:47:19 PM